OneMedNet Corp (ONMD): R&D Expense

Annual figures by period end, from SEC filings.

$1.51M
Year ended 2025-12-31
$1.40M
Trailing 12 months to 2026-06-30
-1.6%
3-year compound annual growth
$2.06M2022-12-31: $1.59M2023-12-31: $2.06M2024-12-31: $1.47M2025-12-31: $1.51M$1.51M
2022-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$1.51M+3.3%2026-03-30, From 2025-01-01
2024-12-31$1.47M-29.0%2026-03-30, From 2024-01-01
2023-12-31$2.06M+29.8%2025-04-15, From 2023-01-01
2022-12-31$1.59Mn/a2024-11-05, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Services-Commercial Physical & Biological Research), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
OneMedNet Corp (ONMD)2025-12-31$1.51M+3.3%
iSpecimen Inc. (ISPC)2024-12-31$1.49M-7.8%
Absci Corp (ABSI)2025-12-31$81.42M+27.5%
bioAffinity Technologies, Inc. (BIAF)2025-12-31$1.38M-5.3%
Foxo Technologies Inc. (FOXO)2025-12-31$182.5K-41.6%
OmniAb, Inc. (OABI)2025-12-31$47.75M-13.3%
MaxCyte, Inc. (MXCT)2025-12-31$20.82M-6.3%
Incyte Corp (INCY)2025-12-31$2.05B-21.4%

Compare ONMD, ISPC, ABSI, BIAF side by side · Screen every company in Services-Commercial Physical & Biological Research ↗